Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
about
Therapeutic interventions for symptomatic treatment in Huntington's diseaseTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderHistone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regenerationPharmacology of epigenetics in brain disordersPreclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?Use of antiepileptic drugs for hyperkinetic movement disorders.Symptomatic treatment of Huntington diseaseEpigenetic treatment of neurological disease.Targeting Huntington's disease through histone deacetylases.Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?An update and review of the treatment of myoclonus.Huntington's Disease-Update on Treatments.Therapeutics in Huntington's Disease.Recent advances in the management of choreas.Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.Treatment options for chorea.
P2860
Q24239893-AB7D4C70-2380-4325-A29D-4CE6A76CE702Q24626017-D1164043-31B2-4FD3-BE2B-966D6F882A1AQ28080593-3F079B04-6C87-4CFC-BA9C-46D2C261D76CQ33673025-0722FA6A-A024-4C45-8856-293CBDBDBA9DQ34284039-ABF50969-FF5A-4C04-8BD8-7C7A0B416BA3Q34829294-C2735932-277F-4CB0-936C-3FADB48386D1Q37131233-D5296BC7-74F3-47A0-BBD7-B450100F5DEDQ37962584-F79275E2-3132-4B90-AFC8-44A9393D63D1Q38019159-740BFC77-FD5B-493A-A739-3BC54C1E8483Q38215303-5F189E8C-A615-4CC5-8737-6C599BADB357Q38244078-13106041-14CC-423C-9F73-CD5F4BF37CC8Q38268299-1B251FB3-CD73-412E-AA51-7CB4C79FCB41Q39190617-E3971B7A-B6C3-4663-8CBD-5B608FD957AAQ39252195-9B672691-DBE6-438A-B4C5-39BB4E324EA8Q42143817-86E77E25-0BF8-45D4-B2C5-F8D2D676E155Q45303272-DE04C7DF-6A37-4806-A294-CA2252472FEFQ47977953-B3BD4EF3-73EE-44D1-A120-F1147AF918CD
P2860
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Dose-dependent improvement of ...... sease patients: a case series.
@ast
Dose-dependent improvement of ...... sease patients: a case series.
@en
type
label
Dose-dependent improvement of ...... sease patients: a case series.
@ast
Dose-dependent improvement of ...... sease patients: a case series.
@en
prefLabel
Dose-dependent improvement of ...... sease patients: a case series.
@ast
Dose-dependent improvement of ...... sease patients: a case series.
@en
P2093
P2860
P356
P1433
P1476
Dose-dependent improvement of ...... isease patients: a case series
@en
P2093
Horst Przuntek
Juergen E Andrich
Peter H Kraus
Thorsten Lauter
P2860
P2888
P356
10.1186/1471-2377-6-11
P50
P577
2006-02-28T00:00:00Z
P5875
P6179
1008949972